Introduction
The efficacy of short-term administration of nitrates for treating myocardial infarction during the acute phase has been well established (1) (2) (3) . In 1999, the Committee on Management of Acute Myocardial Infarction reported that intravenous nitroglycerin was not useful for patients with systolic blood pressure (SBP) less than 90 mmHg or bradycardia less than 50 bpm (4). In 1993, the United States Food and Drug Administration Cardio-Renal Drugs Advisory Committee (5) concluded in their "Pink Sheet" that oral anti-anginal nitrates should be indicated only for single-i.e., not chronic-use, pending the availability of long-term data. The GISSI-3 (6) sponsible for nitrate tolerance has improved, particularly with respect to the documentation of neurohumoral activation (16) during nitrate therapy, there have been increasing concerns about the potential for rebound after patch removal during intermittent therapy. Rebound is a possible explanation for the reported increase in rest angina during the patchoff period in some patients receiving intermittent therapy with nitroglycerin (14, 17) . The purpose of the present study was to clarify the risk of cardiac events by eccentric dosing of nitrates in patients with healed myocardial infarction.
Methods

Recruitment of Patients
The participants in this clinical trial were 573 consecutive myocardial infarction patients in our department. Enrollment in the trial began in January 1997 and ended in December 1999. Patients of either gender and any age experiencing myocardial infarction during this period were eligible, including both inpatients and outpatients. Those who came to the outpatient clinic were registered on their first visit during the study period. Among inpatients, diagnosis of acute myocardial infarction was based on patient history, electrocardiographic changes compatible with acute myocardial infarction, and significant elevation of myocardial serum enzymes. Diagnosis of healed myocardial infarction was made from the characteristic electrocardiographic evidence of past myocardial infarction, with or without taking a history, and in the case of those who consulted our outpatient clinic, from medical documentation of acute myocardial infarction from the referring hospital.
Assignment, Prescription and Follow-Up
Each patient was assigned an eight-digit identification number by the hospital administration on the first visit to our hospital before consultation by any doctors. Group assignment was performed using the 3rd-to-the-last digit of the identification number: if the digit was even (e.g., 99999299), the patient received nitrates treatment; if the digit was odd (e.g., 99999199), the patient was assigned to the untreated group. In both groups, sublingual or intravenous isosorbide dinitrate as well as nitroglycerin were used as required during the acute phase of myocardial infarction.
Nitrates used for the treated group consisted of oral isosorbide dinitrate 20 mg or isosorbide mononitrate 20 mg twice a day (once each after breakfast and supper) or three times a day (once after each meal). The isosorbide dinitrate patches (40 mg) or nitroglycerine patches (25 mg) were applied for 24 h, and new patches were applied each morning or evening. Eccentric dosing of nitrate treatment consisted of oral isosorbide dinitrate 20 mg or isosorbide mononitrate 20 mg once a day (after breakfast) or twice a day (after breakfast and lunch). The isosorbide dinitrate patches (40 mg) or nitroglycerine patches (25 mg) were applied for 12 h, and new patches were applied each morning or evening. The nitrate prescriptions in both the continuous and eccentric treatments are shown in Table 1 . The choice of oral (p.o.) or transdermal (patch) administration was made by the attending physician, as was the selection of eccentric or continuous dosing of nitrate treatment. Outpatient visits were scheduled approximately once a month after assignment during the study period. Informed consent was obtained before study entry. All studies were approved by the institutional review board.
Follow-Up Examinations
Inpatient heart rates and blood pressures were obtained as the daily means of the measurements made by the ward nurses at vital check-ups. Outpatient heart rates were measured from electrocardiograms recorded during follow-up, while the patients were at rest in the supine position in the electrocardiogram laboratory. Blood pressures for these patients were obtained as the means of casual blood pressures measured at our outpatient clinic. Serial blood tests, exercise electrocardiograms, and echocardiograms were administered to inpatients several times during their hospitalization, and approximately twice yearly to those treated in our outpatient clinic. Clinical severity during the acute phase was assessed by the Forrester (18) and Killip (19) classifications. Abnormalities in left ventricular wall motion were assessed by the wall motion index on 2-dimensional echocardiograms (20) .
Electrocardiogram QRS scores were determined to evaluate the extent of myocardial infarction (21) . Angina pectoris during follow-up after myocardial infarction was diagnosed on the basis of the characteristic chest pain and prompt relief of the symptoms with sublingual nitroglycerin. Variant angina during follow-up was also diagnosed on the basis of chest pain as described by Prinzmetal et al. (22) , prompt relief with sublingual nitroglycerin, with or without electrocardiographic evidence of transient ST segment elevation on the ambulatory electrocardiogram, and a positive response to provocation by ergonovine or acetylcholine. The exercise electrocardiogram was defined as positive if the patients showed a positive response in either Master's two-step test or a treadmill exercise test.
Exclusions and Discontinuation
Patients admitted to the hospital who survived 7 days after the onset of acute myocardial infarction were enrolled in the study; patients who died within 7 days after onset were excluded. Trial deviation was defined as discontinuation of study medication for more than 1 month for any reason other than a cardiac event or a doctor's referral. When patients deviated from the protocol, they were dropped from the database. Investigation was continued in patients who received percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG).
Cardiac Events
The cardiac events of interest were nonfatal recurrent myocardial infarction, fatal recurrent myocardial infarction, death from congestive heart failure, and sudden death, worsening angina and rebound angina. Diagnosis of a recurrent myocardial infarction was made on the basis of the same criteria as the qualifying myocardial infarction for patient enrollment. Diagnosis of congestive heart failure was made from the signs and symptoms compatible with congestive heart failure, with or without echocardiographic, roentgenographic or hemodynamic evidence of heart failure. Diagnosis of death from congestive heart failure was established when the cause of death was directly attributable to congestive heart failure. Sudden death, in accordance with Braunwald's definition (23) , was defined as death occurring unexpectedly with no premonitory symptoms or with symptoms lasting no longer than 1 h. Worsening angina was defined as an exacerbation of a patient's usual symptoms requiring emergency hospital admission, and accompanied by objective evidence of ischemia from new or dynamic electrocardiographic abnormalities, a new or unequivocal regional wall motion abnormality, or scintigraphic perfusion defect indicating ischemia and extending over 2 myocardial segments (24) . Rebound angina was defined as the increased frequency of angina attacks associated with decreased blood nitrate levels during nitrate-free intervals in patients receiving intermittent nitrate administration (25) . 
Statistical Analysis
Data are reported as the means SD. Two tailed values of p<0.05 were considered statistically significant. The comparability of the baseline characteristics of the three groups was ascertained by χ 2 tests for categorical variables. The study's primary endpoint (cardiac events) was a composite of nonfatal recurrent myocardial infarction, fatal recurrent myocardial infarction, death from congestive heart failure, and sudden death. Incidence rates of the cardiac events were calculated by dividing the numbers of events by the numbers of patients at follow-up for each of the three groups. To correct for the differences in the numbers of the patients and in the durations of the follow-up periods, the frequencies of cardiac events were expressed per 1,000 person·year. To assess the potential effect of patients' characteristics on outcome, subgroup analyses were performed by stratifying all 46 variables. Event-free ratios for patients with and without nitrates were estimated by the Kaplan-Meier method. Multivariate analysis was performed by the Cox hazard model. The hazard ratios and 95% confidence intervals for each variable were calculated.
Results
Patients' Characteristics
The 573 participants registered during the 36-month study included 468 males and 105 females, and 61 inpatients and 512 outpatients (Table 2 ) with healed myocardial infarction. The mean observation period was 11.2 8.2 months. The total of 573 patients were divided into two groups: a group treated with nitrates (n 239) and a nontreated group (n 334). The nitrate-treatment group was subdivided into a group receiving eccentric dosing (n 153) and a group receiving continuous dosing (n 86) of nitrates.
Success of Assignment and Follow-Up
Among the 334 patients in the nontreatment group, 214 patients (64.1%) did not receive nitrates according to the assign- 
Cardiac Events and Mortality
The incidence of cardiac events was significantly greater in the patients with continuous dosing of nitrates than in the nontreated patients (Table 3) . To normalize the number of patients and the follow-up period, the incidence of cardiac events was divided by the number of 1,000 patients in each group and the length of follow-up in years (cardiac events/ 1,000 person·year). The incidence of cardiac events/1,000 person·year was significantly greater in the patients with continuous dosing of nitrates (67.4/1,000 person·year) than in the nontreated patients (19.7/1,000 person·year) ( p<0.05). The incidence of cardiac events/1,000 person·year was not significantly greater in the patients with eccentric dosing of nitrates (12.7/1,000 person·year) compared with the nontreated patients. There was no significant increase in worsening angina or rebound angina in the patients with eccentric dosing of nitrates. The patients without nitrate treatment had a higher survival rate than the patients receiving continuous dosing of nitrates ( p<0.01) (Fig. 1) . However, there was no significant difference between the untreated patients and the patients treated with eccentric dosing of nitrates. The proportional hazards approach is a multivariate analysis and uses information from all patients in a trial. This analysis confirmed that long-term, continuous dosing of nitrates was worse in the patients with healed myocardial infarction (hazard ratio, 5.74; 95% confidence interval, 1.26-26.21; p 0.0241) (Fig. 2) .
Subgroup Characteristics
The subgroup characteristics of the patients in the three groups are shown in Table 4 . Patients were divided into subgroups based on their use and kind of nitrates and the occurrence of cardiac events. The incidence of cardiac events was compared in relation to age, interval from onset to registry, number of coronary vessels involved, angina pectoris, hypertension, triglycerides and β-blockers. Among the patients with hypertension, those receiving continuous dosing of nitrates had a higher number of cardiac events than those not treated with nitrates ( p<0.05) ( Table 4) . Among the patients with hyperlipidemia, those receiving continuous dosing of nitrates had a higher number of cardiac events than those not treated with nitrates ( p<0.01). Among the patients with involvement of a number of coronary vessels, angina pectoris, or β-blockers, those receiving continuous dosing of nitrates had a higher number of cardiac events than those not treated with nitrates; however, these differences were not significant. 
Discussion
Effects of Short-or Long-Term Nitrate Treatment for Acute Myocardial Infarction
Several clinical studies have examined the effects of shortterm nitrate treatment for acute myocardial infarction. Cardiac events occurring within 7 days after onset of myocardial infarction were not counted in our present study, which duration was considered sufficient to yield results different from those of the previous studies. Yusuf et al. (3) included the patients receiving nitrates within 7 days after the onset of acute myocardial infarction, and concluded that oral or intravenous nitrate treatment during the acute phase of myocardial infarction reduced cardiac mortality. They showed that the greatest reduction in mortality occurred in the first week, with a nonsignificant reduction thereafter. Jugdutt (1) reported that, in the first 48 h after acute myocardial infarction, intravenous nitroglycerin infusion resulted in fewer deaths both in-hospital and for up to 1 year. The effect of long-term nitrate treatment is not well known. Rapaport (26) retrospectively reported the effect of isosorbide dinitrate in 139 patients followed-up for an average of 11 months. Twentythree of the 90 patients (25.6%) not receiving isosorbide dinitrate died; however, only 5 of 49 patients (10.2%) receiving isosorbide dinitrate died ( p<0.05). His data was not conclusive because of the relatively small number of cases. Rossetti et al. (27) showed that nitroglycerin lessens symptoms but is ineffective for long-term prophylaxis of silent myocardial ischemia. Fitzgerald and Bennet (2) conducted a multicenter, randomized trial of oral isosorbide 5-mononitrate in 360 patients with acute myocardial infarction. The overall 6-month mortality in the group receiving the drug was 14.1%, vs. 10.5% in the controls (NS). In 1993, the FDA CardioRenal Drugs Advisory Committee (5) concluded that oral nitrates should be indicated only for single-i.e., not chronicuse, pending the availability of long-term data. In the GISSI-3 (6) and ISIS-4 (7) trials, there was no significant reduction in 5 or 6 week mortality by nitrates. Ishikawa et al. (8) first reported that long-term nitrate treatment increased the incidence of cardiac events among patients with healed myocardial infarction. A total of 1,002 patients with healed myocardial infarction were divided into nitrate-treatment and notreatment groups. Among 621 patients treated with nitrates, 6.6% (n 41) experienced cardiac events, which was significantly ( p<0.05) greater than the 3.1% (12 of 318) of patients not receiving nitrates who experienced such events. Consistent with those findings, a retrospective analysis by Nakamura et al. (9) indicated that long-term nitrate use may be deleterious in ischemic heart disease. When they analyzed data from 1,042 patients enrolled in the Multicenter Study of Myocardial Ischemia (MSMI) and from 1,779 patients enrolled for the Multicenter Diltiazem Post Infarction Trial (MDPIT), they found that nitrates were associated with a significantly increased mortality risk in patients who had recovered from an acute coronary event.
Possible Mechanisms of the Increase in Cardiac Events by Nitrates
Cardiac events in the patients with nitrates may have been caused by nitrate tolerance (28) (29) (30) (31) , neurohumoral effects (28, 32, 33) , rebound phenomena (25, 34) , and/or hypervascular response of coronary arteries (35) (36) (37) . With oral or transdermal nitrates, nitrate tolerance developed within days or weeks (28, 29) . Increased plasma epinephrine, norepinephrine and renin activity in patients receiving nitrates may increase the deleterious effects. Reflex neurohumoral activation initiated by nitrates (28, 32, 33) may also play a role in increasing cardiac events. Reeves et al. (34) reported in a rabbit experiment that abrupt withdrawal of nitroglycerin and subsequent administration of ergonovine and indomethacin probably induced the coronary artery spasm that caused the myocardial ischemia, ventricular arrhythmia and myocardial infarction. Frishman (25) emphasized that some patients experience exacerbation, or rebound, of anginal symptoms and a worsening of exercise tolerance at the end of a nitroglycerin-free period.
Deterioration of Benefits with Continuous Dosing of Nitrates
There have been several reports concerning the unusual vasomotor coronary arterial responses after nitroglycerin (38, 39) . Feldman et al. (38) reported that, in two patients, right coronary arterial segments that appeared angiographically normal before the administration of nitroglycerin showed narrowing after nitroglycerin was administered. Bove and Vlietstra (39) reported that coronary angiograms compared before and after nitroglycerin administration revealed a reduction in stenosis diameter. Coronary arterial responses to some vasoactive substances may also be qualitatively altered by nitrate therapy. When Caramori et al. (40) used quantitative angiography to measure changes in the mean luminal diameter of the left anterior descending coronary artery elicited by intracoronary acetylcholine, they found that patients receiving continuous transdermal nitroglycerin (0.6 mg/h) exhibited greater coronary arterial constriction in response to acetylcholine infusion than those not receiving nitroglycerin. It was concluded that continuous transdermal nitroglycerin caused abnormal coronary vasomotor responses to acetylcholine, which is normally an endothelium-dependent vasodilator.
Increase of Cardiac Events by the Combination of Hypertension and Continuous Dosing of Nitrates
Angiotensin converting enzyme inhibitors, Ca antagonists, and HMG-CoA reductase inhibitors improve the endothelial function in hypertensives (41, 42) . Conversely, smoking raises the risk of strokes in hypertensive men (43) . In this study, among the patients with hypertension, patients receiving continuous dosing of nitrates had higher cardiac events than the untreated patients. High blood pressure plays a critical role in serious cardiac events in hypertensive patients with moderate coronary artery lesions (44) . Also, in this study, antihypertensive therapy for hypertensive patients with healed myocardial infarction was selected by the attending physicians. Physicians' attitudes towards antihypertensive therapy plays a crucial role in achieving an adequate blood pressure (45) . Long-term treatment with high doses of nitroglycerin has been associated with increased sensitivity to α-adrenergic stimuli (35) (36) (37) . Platelet aggregation has been shown to be promoted in patients having lesions with one or more complex morphologic features (46) , during coronary vasospasm (47) , and during nonischemic intervals in patients with vasospastic angina (48) . Finally, continuous dosing of nitrates seems to enhance endothelial damage in hypertensives.
Benefits of Eccentric Dosing of Nitrates
Intermittent nitrate therapy increases exercise duration and maintains anti-ischemic effects, without significant evidence of nitrate tolerance or rebound phenomenon (17, (49) (50) (51) (52) . Although intermittent nitrate therapy has proved superior to continuous therapy, intermittent therapy may be associated with rebound myocardial ischemia during the nitrate-free period. Patients receiving intermittent nitroglycerin therapy may therefore have an increase in angina at rest or suffer a fatal myocardial infarction (14, 17, 53) . Although these reports are a cause of concern, no such effects were reported in a recent large trial of intermittent transdermal nitroglycerin therapy (49) . Intermittent administration of nitrates does not cause rebound angina and is therefore safe (54) . In light of these results, no firm conclusions can be drawn concerning the risk of acute ischemic events during intermittent nitrate therapy. Intermittent transdermal nitroglycerin therapy also has adverse effects on performance on treadmill exercise tests during the period of withdrawal from nitrates. Adverse effects on exercise tolerance have not been reported in studies of other long-acting nitrates given once daily or in eccentric dosing regimens (55, 56) . The mechanism of adverse responses during the nitrate-free interval of intermittent transdermal nitroglycerin therapy is unclear, but they may be due to a heightened sensitivity to vasoconstrictors. In animals, withdrawal of nitrate therapy has been associated with a decrease in the diameter of the epicardial coronary arteries, which was prevented by the concurrent administration of high doses of enalapril (57) . Whether these responses are related to clinical events that occur after nitrate withdrawal is unclear. No information is available concerning such adverse effects during eccentric dosing with isosorbide nitrate. Isosorbide mononitrate has not been reported to cause either rebound ischemia or adverse effects on exercise performance (55, 56, 58) .
Study Limitations
The present study was an open clinical trial. A randomized, placebo-controlled, double-blind trial would be preferable. However, the incidence of cardiac events was significantly greater in patients receiving continuous dosing of nitrates compared than in the controls. The difference in patient profiles among the three groups was caused by the incomplete assignment and selection of eccentric or continuous dosing of nitrate treatment by the attending physician. However, a multivariate analysis confirmed that continuous dosing of long-term treatment with nitrate was more deleterious in patients with healed myocardial infarction.
In conclusion, continuous dosing of nitrates is deleterious in patients with healed myocardial infarction. Eccentric dosing of nitrates does not increase cardiac events in such patients, but is also not effective for preventing them.
